Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis

THOUSAND OAKS, Calif. and TOKYO: Agreement Renews Successful Global Collaboration That led to Several Groundbreaking Therapies in Multiple Disease Areas KHK4083 Depletes OX40-Expressing T cells Associated with Atopic Dermatitis and Several Other Inflammatory Diseases Moderate-to-Severe Atopic Dermatitis Affects Nearly 30 Million People in Major Global Markets1 Amgen to Host Investor...

Click to view original post